BioSpace News Archive

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced today that it has received a target action date of August 4, 2022 from the U.S. Food and Drug Administration (FDA) for its resubmitted supplemental New Drug Application (sNDA) for pimavanserin for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP).

Vaccinex, Inc. announced that it has been selected for poster presentation related to the phase 1b segment of its KEYNOTE-B84 study of pepinemab in combination with KEYTRUDA in patients with recurrent or metastatic head and neck cancer during the upcoming 2022 American Association for Cancer Research Meetings, taking place from April 8th to April 13th in New Orleans via in person and virtual attendance.

Akorn Operating Company LLC, a leading specialty pharmaceutical company, announced the completion of its previously announced sale of seven branded ophthalmic products to Théa Pharma.

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) (“CNS” or the “Company”), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today released a video to shareholders reiterating its operational and clinical progress for lead product candidate, Berubicin, and addressing recent share price activity.

C2Dx, a privately held medical device company, announced its acquisition of Hemostatix Medical Technologies LLC (Hemostatix) effective on January 1, 2022.

Romark announced today that results of its Vanguard Co-V clinical trial of NT-300 (nitazoxanide extended-release tablets, 300 mg) for treatment of mild or moderate COVID-19 have been published in Lancet’s eClinicalMedicine.

ONWARD Medical N.V., the medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injury, announces the start of enrollment in the LIFT Home Study.

Curia announced a cooperative agreement with the BARDA, part of the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response, the Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense and the U.S. Army Contracting Command to support the domestic production of injectable medicines.

Rise in geriatric population and growing burden of chronic diseases such as obesity and diabetes worldwide are among the key factors driving the global Patient Engagement Solutions market revenue growth.

Rapid digitalization in the healthcare sector, rising adoption of electronic health records and need for secure data exchange, and growing focus on improving patient outcomes are some key factors expected to drive Interoperability Solutions in Healthcare market growth.